Copanlisib (Aliqopa™): First Global Approval – First of its kind to offer hope to patients with relapsed follicular lymphoma

Copanlisib (Aliqopa™): First Global Approval – First of its kind to offer hope to patients with relapsed follicular lymphoma

The recent first global approval of copanlisib has been reviewed in detail in the First Global Approval report in Adis’ journal Drugs[1], based on the development milestones tracked in AdisInsight[2]. Continue reading “Copanlisib (Aliqopa™): First Global Approval – First of its kind to offer hope to patients with relapsed follicular lymphoma”

Abemaciclib (Verzenio™) First Global Approval – Early decision by FDA for new continuous treatment option for metastatic breast cancer

Abemaciclib (Verzenio™) First Global Approval – Early decision by FDA for new continuous treatment option for metastatic breast cancer

The recent first global approval of abemaciclib has been reviewed in detail in the First Global Approval report in Adis’ journal Drugs[1], based on the development milestones tracked in AdisInsight[2]. Continue reading “Abemaciclib (Verzenio™) First Global Approval – Early decision by FDA for new continuous treatment option for metastatic breast cancer”

Antibiotic resistant superbugs – should we be worried?

Antibiotic resistant superbugs – should we be worried?

Post contributed by Glenn Whiteside, Product Specialist for AdisInsight

I have a mate, let’s call him Steve, actually his name is Steve, and several years ago he noticed that the big toe on his right foot was turning black. Diagnosis revealed that he had poor circulation to his lower leg and foot because of venous occlusion caused years ago when he was stomped on in a rugby game. The long and short of it was that his toe needed to be amputated and a stent put into a vessel in his leg to fix the problem. Unfortunately for Steve and the three other guys in his room, they were all infected with MRSA (methicillin resistant Staphlococcus aureus). Steve ended up having two further amputations on his leg to try to stop the spreading infection. He tried every antibiotic in the arsenal, but none of them stopped the relentless progress of the infection, instead the bacteria just kept on eating his tissues. Steve was lucky in a way because he lived to tell his tale, albeit without the lower half of his leg. Continue reading “Antibiotic resistant superbugs – should we be worried?”

1998 Shirov: Bishop to h3! Dubbed an all-time strategic chess move… How do future pharmacovigilance strategies compare?

1998 Shirov: Bishop to h3! Dubbed an all-time strategic chess move… How do future pharmacovigilance strategies compare?

Report: Pharmacovigilance Strategy Meeting, Boston, MA, USA November 2017

In less time than it took for me to travel to the meeting from New Zealand – the day was over! Hard to believe that within a short eight hours, 25 lively roundtables were conducted, two keynote speeches were delivered, and the panel discussed the learning of the day, including challenges of monitoring diverse sources, importance of real-world evidence in the context of risk benefit, and the game-changing impact of artificial intelligence. Continue reading “1998 Shirov: Bishop to h3! Dubbed an all-time strategic chess move… How do future pharmacovigilance strategies compare?”

Tivozanib (Fotiva®): First Global Approval – selective agent for optimal VEGF blockade in adults with renal cell carcinoma.

Tivozanib (Fotiva®): First Global Approval – selective agent for optimal VEGF blockade in adults with renal cell carcinoma.

The recent first global approval of tivozanib has been reviewed in detail in the First Global Approval report in Adis’ journal Drugs[1], based on the development milestones tracked in AdisInsight[2]. Continue reading “Tivozanib (Fotiva®): First Global Approval – selective agent for optimal VEGF blockade in adults with renal cell carcinoma.”